244 related articles for article (PubMed ID: 26011051)
1. Barriers to and facilitators of compliance with clinic-based cervical cancer screening: population-based cohort study of women aged 23-60 years.
Östensson E; Alder S; Elfström KM; Sundström K; Zethraeus N; Arbyn M; Andersson S
PLoS One; 2015; 10(5):e0128270. PubMed ID: 26011051
[TBL] [Abstract][Full Text] [Related]
2. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
3. Women's perceptions and social barriers determine compliance to cervical screening: results from a population based study in India.
Basu P; Sarkar S; Mukherjee S; Ghoshal M; Mittal S; Biswas S; Mandal R; Sankaranarayanan R
Cancer Detect Prev; 2006; 30(4):369-74. PubMed ID: 16963194
[TBL] [Abstract][Full Text] [Related]
4. Assessing the role of education in women's knowledge and acceptance of adjunct high-risk human Papillomavirus testing for cervical cancer screening.
Papa D; Moore Simas TA; Reynolds M; Melnitsky H
J Low Genit Tract Dis; 2009 Apr; 13(2):66-71. PubMed ID: 19387125
[TBL] [Abstract][Full Text] [Related]
5. How can young women be encouraged to attend cervical cancer screening? Suggestions from face-to-face and internet focus group discussions with 30-year-old women in Stockholm, Sweden.
Blomberg K; Tishelman C; Ternestedt BM; Törnberg S; Levál A; Widmark C
Acta Oncol; 2011 Jan; 50(1):112-20. PubMed ID: 21091087
[TBL] [Abstract][Full Text] [Related]
6. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
Wong G; Howard K; Webster A; Chapman JR; Craig JC
Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
[TBL] [Abstract][Full Text] [Related]
7. Competing needs: a qualitative study of cervical cancer screening attendance among HPV-positive women in Tanzania.
Linde DS; Rasch V; Mwaiselage JD; Gammeltoft TM
BMJ Open; 2019 Feb; 9(2):e024011. PubMed ID: 30819704
[TBL] [Abstract][Full Text] [Related]
8. Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening.
Darlin L; Borgfeldt C; Forslund O; Hénic E; Hortlund M; Dillner J; Kannisto P
J Clin Virol; 2013 Sep; 58(1):155-60. PubMed ID: 23867008
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
[TBL] [Abstract][Full Text] [Related]
11. Impact of pap test compliance and cervical cancer screening intervals on human papillomavirus vaccine acceptance.
Ferris DG; Waller J; Dickinson A; McCracken C; Goebel A
J Low Genit Tract Dis; 2012 Jan; 16(1):39-44. PubMed ID: 22126831
[TBL] [Abstract][Full Text] [Related]
12. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
[TBL] [Abstract][Full Text] [Related]
13. Screening for breast and cervical cancer in a large German city: participation, motivation and knowledge of risk factors.
Klug SJ; Hetzer M; Blettner M
Eur J Public Health; 2005 Feb; 15(1):70-7. PubMed ID: 15788807
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
Holmes J; Hemmett L; Garfield S
Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
[TBL] [Abstract][Full Text] [Related]
15. Costs of integrating cervical cancer screening at an HIV clinic in Kenya.
Vodicka EL; Babigumira JB; Mann MR; Kosgei RJ; Lee F; Mugo NR; Okech TC; Sakr SR; Garrison LP; Chung MH
Int J Gynaecol Obstet; 2017 Feb; 136(2):220-228. PubMed ID: 28099724
[TBL] [Abstract][Full Text] [Related]
16. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
Brown RE; Breugelmans JG; Theodoratou D; Bénard S
Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
[TBL] [Abstract][Full Text] [Related]
17. Cervical-cancer screening: attendance and cost-effectiveness.
Koopmanschap MA; van Oortmarssen GJ; van Agt HM; van Ballegooijen M; Habbema JD; Lubbe KT
Int J Cancer; 1990 Mar; 45(3):410-5. PubMed ID: 2106499
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
19. Estimating time and travel costs incurred in clinic based screening: flexible sigmoidoscopy screening for colorectal cancer.
Frew E; Wolstenholme JL; Atkin W; Whynes DK
J Med Screen; 1999; 6(3):119-23. PubMed ID: 10572841
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of cervical-cancer screening in five developing countries.
Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
